Martin Auster Analyst PerformanceManaging Director Biotechnology at Raymond James FinancialMartin Auster is a stock analyst at Raymond James Financial in the medical sector, covering 15 publicly traded companies. Over the past year, Martin Auster has issued 3 stock ratings, including strong buy and buy recommendations. While full access to Martin Auster's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Martin Auster's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Ratings, Coverage, and Performance StatisticsAnalyst RatingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings49 Last 6 YearsBuy Recommendations62.50% 30 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution48RatingsDistribution of strong buy, buy, hold, and sell ratings by Martin Auster.RatingPercentageCount Strong Buy2.1%1 ratings Buy60.4%29 ratings Hold33.3%16 ratings Sell4.2%2 ratingsOut of 48 total stock ratings issued by Martin Auster at Raymond James Financial, the majority (60.4%) have been Buy recommendations, followed by 33.3% Hold, 4.2% Sell, and 2.1% Strong Buy.Best & Worst CallsBest Call0000.0%RARXOct 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ANABNov 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ15 companiesMartin Auster, an analyst at Raymond James Financial, currently covers 15 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies100.0%Martin Auster of Raymond James Financial specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies40.0%MED - DRUGS3 companies20.0%PHARMACEUTICAL PREPARATIONS3 companies20.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC3 companies20.0% About Martin AusterMartin Auster joined Raymond James in 2025 and covers the biotechnology industry. Previously, he served as chief financial officer at Ventyx biosciences from 2021-2024 and was a research analyst at UBS Securities LLC from 2016-2017 and at Credit Suisse Securities (USA) LLC from 2017-2021. Prior to that, Dr. Auster held the positions of chief business officer at Ascendis Pharma from 2014- 2016 and VP-business development & strategic finance at United Therapeutics Corp. from 2009-2014. Earlier in his career, he served as a senior equity analyst at Truist Securities, Inc., as a senior biotechnology analyst at Wachovia Securities LLC, and as a portfolio manager at GLG Partners, Inc. Dr. Auster completed his undergraduate degree at the University of Michigan and obtained a doctorate from the University of Texas Medical Branch at Galveston.Follow on LinkedIn Martin Auster's Ratings History at Raymond James Financial Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDYNDyne Therapeutics8/25/2025Upgrade$12.58$35.00Strong-Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals7/30/2025Initiated Coverage$330.55$370.00Outperform$0.0000.00% ROIDYNDyne Therapeutics7/29/2025Reiterated Rating$9.14$31.00Outperform$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
